Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Life & the LawPeer ReviewedChemical Abortion Issues in Law & Medicine

Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient from September 2000 to February 2019

Additional Authors: Benjamin D. Beran M.D.; Michael D. Lockwood D.O; Sigmund Seiler M.D.

ABSTRACT:

Objectives: Primary:

Analyze the Adverse Events (AEs) reported to the Food and Drug Administration (FDA) after use of mifepristone as an abortifacient.

Secondary:

Analyze maternal intent after ongoing pregnancy and investigate hemorrhage after mifepristone alone.

Methods:

Adverse Event Reports (AERs) for mifepristone used as an abortifacient, submitted to the FDA from September 2000 to February 2019, were analyzed using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAEv3).

Results:

The FDA provided 6158 pages of AERs. Duplicates, non US, or AERs previously published (Gary, 2006) were excluded. Of the remaining, there were 3197 unique, US-only AERs of which there were 537 (16.80%) with insufficient information to determine clinical severity, leaving 2660 (83.20%) Codable US AERs (Figure 1). Of these, 20 were Deaths, 529 were Life-threatening, 1957 were Severe, 151 were Moderate, and 3 were Mild.

Read Complete Article

Latest Posts

December 7, 2023 Understanding Women’s Communication with Their Providers During Medication Abortion and Abortion Pill Reversal: An Exploratory Analysis Understanding Women’s Communication with Their Providers During Medication Abortion and Abortion Pill Reversal: An Exploratory Analysis December 7, 2023 Medication Abortion and Abortion Pill Reversal: An Exploratory Analysis on the Influence of Others in Women’s Decision-Making Medication Abortion and Abortion Pill Reversal: An Exploratory Analysis on the Influence of Others in Women’s Decision-Making November 20, 2023 Hoja Informativa: Riesgos y Complicaciones del Aborto Químico

You Might Also Be Interested In

Why We Need Federal Limits on Late Abortion to Protect Both Mother and Child

October 2, 2023
ClosePlease loginn
Abortion “Shield Laws”: Pro-Abortion States Seek to Force Abortion on Life-Affirming States

Abortion “Shield Laws”: Pro-Abortion States Seek to Force Abortion on Life-Affirming States

August 24, 2023
ClosePlease loginn

The Life-Saving Impact of State Actions Following the Dobbs Decision: A Case Study of Plummeting 2022 Abortion Totals in Oklahoma and Arkansas

July 14, 2023
ClosePlease loginn

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image